GSK-Vir COVID therapy Sotrovimab authorization junked by USFDA

The U.S. health regulator said on Tuesday GlaxoSmithKline and Vir Biotechnology's antibody therapy was no longer authorized as a COVID-19 treatment, with data suggesting it was unlikely to be effective against the dominant Omicron sub-variant in the country.

The move by the agency, which had already pulled its authorization for the sotrovimab therapy in much of the U.S. northeast last month, sent shares in Vir Biotechnology 11.5% lower.

For more information, check out the full story on the link:

USFDA Junks Authorization Of GSK- Vir COVID Therapy Sotrovimab